It has become more and more common for patients with chronic diseases to have serious problems with their physical and mental health.
This year, the latest data from the World Health Organization (WHO) shows that Crohn and Colitis (CAD) is the second most common chronic disease globally, after Type 1 Diabetes.
This has led to an increased need for a new way of diagnosing the disease, and an urgent need for new tools to help patients to manage their illness.
In 2016, more than 20 million people worldwide were diagnosed with Crohn disease, the second leading cause of disability worldwide after diabetes.
The new WHO data also show that people in the Western world are living longer, but this does not mean that the global burden of the disease has declined.
The WHO’s 2016 report on the world’s burden of disease noted that, while global deaths from all causes declined by 16 million between 2014 and 2016, mortality from CID decreased by almost 15 million.
This trend was due to a number of factors, including a reduction in the use of antibiotics, a decrease in the incidence of drug-resistant infections, and a shift to a low- or middle-income country.
However, while the overall global burden from CIDs decreased by 15 million, the WHO report noted that this was due in large part to the reduction in drug- resistant infections, particularly in countries with relatively high rates of the condition, such as South Africa and the Democratic Republic of the Congo.
The report also noted that a decrease of around 16 million deaths in the western world could be attributed to the global shift away from antibiotics, as well as the use and availability of alternative medicine.
This is because people in many countries, such a Australia and New Zealand, are increasingly adopting alternative health approaches.
However there is still a large gap between the WHO’s figures and those of other experts.
According to the World Federation of Societies for Experimental Biology, there are currently 1.2 billion people worldwide living with Crohns and the other related chronic diseases, but only around 100 million have been diagnosed with the disease.
A study published in the journal PLOS One by scientists at Johns Hopkins University, found that this gap could be closing as the world ages.
The study examined data from 11 countries in Africa and Asia, where the prevalence of the illness was highest.
It found that the number of people living with CIDs in these countries has increased by about one-third in the last decade, compared to the previous 10 years.
However this could be due to better diagnosis, better treatment and better public awareness.
Dr John Fagan, an expert on the role of new therapies in the field of CIDs, said:”CIDs is an enormously complex disease, but it is an increasingly common and increasingly severe condition that is getting more severe, more prevalent, and more expensive every year.”
The findings show that in Africa, which has the highest proportion of people with the condition in the world, it is also the fastest growing region, with more than half of the population living with the illness.
This could mean that in the future the burden of Crohn could decrease by the same proportion as it has in Africa.
Dr Fagan also pointed out that the diagnosis of Crohneus colitis has been around for a long time, and has now become the standard for people to treat in their medical care.
“There is no question that this diagnosis is increasingly important and has helped improve the lives of many patients, as the disease progresses,” he said.
Dr Hadi Makhlouf, director of the Crohn Disease and Related Disorders Program at Johns Wayne State University, added:”The findings are extremely important because it points to the need for improved clinical management and improved biomarkers to better identify patients with CID.
It is not surprising that more and better technologies have emerged to help diagnose and manage the condition.”
He added that these tools could be particularly useful in the developing world, where there are few tests available to diagnose and monitor people’s disease.
“With the advent of new diagnostic tools, more and higher-quality diagnostic tests are now available for the diagnosis and monitoring of chronic diseases in the developed world,” he told The Guardian.
“But the diagnosis, testing and monitoring needs to be expanded in order to meet the increased demand.”
Dr Makhfouf believes that we will see improvements in diagnosing CIDs by 2026, when the first new biomarker is introduced to the world.
The International Crohn & Colitis Society is the global organisation of leading medical researchers and doctors in the fields of Crohe-N-Hind for Crohn-Colitis and other chronic diseases.